Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
VYNE Therapeutics expects cahs to be sufficient through Dec. 31, 2021 » 07:38
11/05/20
11/05
07:38
11/05/20
07:38
VYNE

VYNE Therapeutics

$1.71 /

-0.06 (-3.39%)

As of September 30, 2020,…

As of September 30, 2020, VYNE had cash, cash equivalents and investments of $76.9 million. We believe that our cash and cash equivalents and investments and projected cash flows from revenues will provide sufficient resources for our current ongoing needs through December 31, 2021.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

Earnings
VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) » 07:37
11/05/20
11/05
07:37
11/05/20
07:37
VYNE

VYNE Therapeutics

$1.71 /

-0.06 (-3.39%)

Reports Q# revenue…

Reports Q# revenue $3.27M, consensus $3.25M. "The launch of ZILXI on October 1st means that VYNE now has two commercial products in the dermatology market. Our immediate priorities for ZILXI are to leverage our sales organization and physician experience with AMZEEQ(R) to drive rapid uptake, and to gain broad payor acceptance and reimbursement," said David Domzalski, Chief Executive Officer of VYNE. "For AMZEEQ, we are pleased to see that prescriptions have eclipsed pre-COVID levels for the first time since the shut down in March and that the overall market in acne continues to recover."

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.71 /

-0.06 (-3.39%)

Conference/Events
VYNE Therapeutics management to meet virtually with Cantor Fitzgerald » 04:55
10/29/20
10/29
04:55
10/29/20
04:55
VYNE

VYNE Therapeutics

$1.62 /

-0.18 (-10.00%)

Virtual Meetings to be…

Virtual Meetings to be held October 28-29 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.62 /

-0.18 (-10.00%)

VYNE VYNE Therapeutics
$1.62 /

-0.18 (-10.00%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.62 /

-0.18 (-10.00%)

Conference/Events
VYNE Therapeutics management to meet virtually with Cantor Fitzgerald » 04:55
10/28/20
10/28
04:55
10/28/20
04:55
VYNE

VYNE Therapeutics

$1.80 /

-0.02 (-1.10%)

Virtual Meetings to be…

Virtual Meetings to be held October 28-29 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.80 /

-0.02 (-1.10%)

VYNE VYNE Therapeutics
$1.80 /

-0.02 (-1.10%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.80 /

-0.02 (-1.10%)

Over a month ago
Conference/Events
VYNE Therapeutics management to meet virtually with Cantor Fitzgerald » 12:14
10/21/20
10/21
12:14
10/21/20
12:14
VYNE

VYNE Therapeutics

$1.85 /

-0.085 (-4.39%)

Virtual Meetings to be…

Virtual Meetings to be held October 28-29 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.85 /

-0.085 (-4.39%)

VYNE VYNE Therapeutics
$1.85 /

-0.085 (-4.39%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.85 /

-0.085 (-4.39%)

Hot Stocks
VYNE Therapeutics announces covered status for ZILXI with Express Scripts » 08:20
10/07/20
10/07
08:20
10/07/20
08:20
VYNE

VYNE Therapeutics

$1.75 /

-0.06 (-3.32%)

VYNE Therapeutics…

VYNE Therapeutics announced a coverage update for its novel ZILXI topical foam, 1.5%. ZILXI is an FDA approved minocycline product for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts has elected to cover ZILXI effective October 2, 2020 on Express Scripts' National Preferred, Flex, and Basic commercial formularies, representing millions of additional covered lives in the U.S. that follow these formularies. The annual list price of ZILXI is $485 per 30-gram canister. ZILXI was approved by the U.S. Food and Drug Administration in May 2020.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

Hot Stocks
VYNE Therapeutics' Zilxi topical foam now covered by Express Scripts » 08:12
10/07/20
10/07
08:12
10/07/20
08:12
VYNE

VYNE Therapeutics

$1.75 /

-0.06 (-3.32%)

VYNE Therapeutics…

VYNE Therapeutics announced a coverage update for its novel ZILXI topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts, a pharmacy benefit manager, has elected to cover ZILXI effective October 2 on Express Scripts' National Preferred, Flex, and Basic commercial formularies. The annual list price of ZILXI is $485 per 30-gram canister. ZILXI was approved by the FDA in May.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$1.75 /

-0.06 (-3.32%)

Recommendations
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright » 06:10
10/05/20
10/05
06:10
10/05/20
06:10
VYNE

VYNE Therapeutics

$1.62 /

-0.015 (-0.92%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat raised the firm's price target on VYNE Therapeutics to $3.50 from $3 and reiterates a Buy rating on the shares. Amzeeq growth is on track, and Zilxi is about to launch with "coverage out of the gate and dermatologists eager for better rosacea treatment," Livnat tells investors in a research note after the company hosted a key opinion leader event.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.62 /

-0.015 (-0.92%)

VYNE VYNE Therapeutics
$1.62 /

-0.015 (-0.92%)

Hot Stocks
VYNE Therapeutics announces nationwide availability of ZILXI topical foam, 1.5% » 07:11
10/01/20
10/01
07:11
10/01/20
07:11
VYNE

VYNE Therapeutics

$1.65 /

+ (+0.00%)

VYNE Therapeutics…

VYNE Therapeutics announced that its novel ZILXI topical foam, 1.5% is available as of today, October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults. Approved by the U.S. Food and Drug Administration in May 2020, ZILXI is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins and acne-like inflammatory lesions. This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide. The Company also announced that the annual list price of ZILXI will be $485 per 30-gram canister, in parity with the wholesale price of AMZEEQ topical foam, 4%, the Company's topical minocycline indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. The Company is working to align contracts with commercial insurers, expanding efforts previously undertaken for AMZEEQ, to offer the broadest possible access to ZILXI for patients and healthcare professionals. VYNE has also developed a multi-channel tactical marketing plan to reach customers, including deployment of the existing sales force to targeted rosacea-treating providers. Minocycline is one of several broad-spectrum antibiotics known as tetracyclines with anti-inflammatory properties; their use in some patients is limited due to systemic side effects when taken orally. In ZILXI, VYNE has once more leveraged its proprietary Molecule Stabilizing Technology platform to effectively deliver minocycline in a foam-based vehicle that contains naturally moisturizing ingredients, such as coconut and soybean oil, and is free of surfactants and drying agents.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.65 /

+ (+0.00%)

VYNE VYNE Therapeutics
$1.65 /

+ (+0.00%)

Options
Seven new option listings and seven option delistings on September 21st » 08:30
09/21/20
09/21
08:30
09/21/20
08:30
BLI

Berkeley Lights

$71.98 /

+5.72 (+8.63%)

, DPHC

DiamondPeak Holdings

$28.92 /

+0.82 (+2.92%)

, HCAC

Hennessy Capital Acquisition

$12.25 /

-0.11 (-0.89%)

, LEGN

Legend Biotech

$32.16 /

-1.43 (-4.26%)

, APVO

Aptevo Therapeutics

$8.00 /

+0.25 (+3.23%)

, CCAP

Crescent BDC

$13.31 /

-0.16 (-1.19%)

, DWSN

Dawson Geophysical

$1.70 /

-0.05 (-2.86%)

, HNRG

Hallador Energy

$0.72 /

-0.0557 (-7.14%)

, MCHX

Marchex

$1.78 /

-0.02 (-1.11%)

, VYNE

VYNE Therapeutics

$1.84 /

+0.03 (+1.66%)

New option listings for…

New option listings for September 21st include S&P 500 ESG (.SPESG), Berkeley Lights Inc (BLI), DiamondPeak Holdings Corporation (Class A Stock) (DPHC), Hennessy Capital Acquisition Corporation IV (Class A Stock) (HCAC), Legend Biotech Corporation (ADS) (LEGN), Proshares Online Retail ETF (ONLN), and Vanguard S&P 500 Growth (VOOG). Option delistings effective September 21st include Aptevo Therapeutics (APVO), Crescent Capital (CCAP), Dawson Geophysical (DWSN), Hallador Energy (HNRG), Marchex (MCHX), Obsidian Energy Ltd (OBELF), and VYNE Therapeutics (VYNE).

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$1.84 /

+0.03 (+1.66%)

MCHX Marchex
$1.78 /

-0.02 (-1.11%)

LEGN Legend Biotech
$32.16 /

-1.43 (-4.26%)

HNRG Hallador Energy
$0.72 /

-0.0557 (-7.14%)

HCAC Hennessy Capital Acquisition
$12.25 /

-0.11 (-0.89%)

DPHC DiamondPeak Holdings
$28.92 /

+0.82 (+2.92%)

APVO Aptevo Therapeutics
$8.00 /

+0.25 (+3.23%)

BLI Berkeley Lights
$71.98 /

+5.72 (+8.63%)

08/11/20
Fly Intel: Top five analyst initiations
08/11/20 JPMorgan
JPMorgan starts 'industry pioneer' Berkeley Lights at Overweight
08/11/20 Morgan Stanley
Berkeley Lights initiated with an Equal Weight at Morgan Stanley
08/11/20 JPMorgan
Berkeley Lights initiated with an Overweight at JPMorgan
DPHC DiamondPeak Holdings
$28.92 /

+0.82 (+2.92%)

09/18/20 Colliers
Lordstown's presentation raised Colliers' expectations for Workhorse valuation
09/17/20 Roth Capital
Roth raises Workhorse target to $33 after Lordstown's 'compelling' analyst day
09/03/20 Oppenheimer
Oppenheimer bullish on Workhorse Group, initiates with an Outperform
08/03/20 Roth Capital
Lordstown's SPAC acquisition driving value for Workhorse, says Roth Capital
HCAC Hennessy Capital Acquisition
$12.25 /

-0.11 (-0.89%)

LEGN Legend Biotech
$32.16 /

-1.43 (-4.26%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
APVO Aptevo Therapeutics
$8.00 /

+0.25 (+3.23%)

08/14/20 Piper Sandler
Aptevo Therapeutics price target raised to $32 from $24 at Piper Sandler
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
05/14/20 Piper Sandler
Aptevo Therapeutics price target lowered to $18.50 from $24 at Piper Sandler
03/25/20 Piper Sandler
Aptevo Therapeutics has $30M in cash, says Piper Sandler
CCAP Crescent BDC
$13.31 /

-0.16 (-1.19%)

02/04/20 Raymond James
Crescent BDC initiated with an Outperform at Raymond James
DWSN Dawson Geophysical
$1.70 /

-0.05 (-2.86%)

HNRG Hallador Energy
$0.72 /

-0.0557 (-7.14%)

MCHX Marchex
$1.78 /

-0.02 (-1.11%)

VYNE VYNE Therapeutics
$1.84 /

+0.03 (+1.66%)

MCHX Marchex
$1.78 /

-0.02 (-1.11%)

LEGN Legend Biotech
$32.16 /

-1.43 (-4.26%)

DWSN Dawson Geophysical
$1.70 /

-0.05 (-2.86%)

BLI Berkeley Lights
$71.98 /

+5.72 (+8.63%)

APVO Aptevo Therapeutics
$8.00 /

+0.25 (+3.23%)

  • 17
    Jul
  • 05
    Jun
DPHC DiamondPeak Holdings
$28.92 /

+0.82 (+2.92%)

LEGN Legend Biotech
$32.16 /

-1.43 (-4.26%)

DPHC DiamondPeak Holdings
$28.92 /

+0.82 (+2.92%)

BLI Berkeley Lights
$71.98 /

+5.72 (+8.63%)

VYNE VYNE Therapeutics
$1.84 /

+0.03 (+1.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.